Unknown

Dataset Information

Mathematical Modeling of Remdesivir to Treat COVID-19: Can Dosing Be Optimized?


ABSTRACT: The antiviral remdesivir has been approved by regulatory bodies such as the European Medicines Agency (EMA) and the US Food and Drug administration (FDA) for the treatment of COVID-19. However, its efficacy is debated and toxicity concerns might limit the therapeutic range of this drug. Computational models that aid in balancing efficacy and toxicity would be of great help. Parametrizing models is difficult because the prodrug remdesivir is metabolized to its active form (RDV-TP) upon cell entry, which complicates dose-activity relationships. Here, we employ a computational model that allows drug efficacy predictions based on the binding affinity of RDV-TP for its target polymerase in SARS-CoV-2. We identify an optimal infusion rate to maximize remdesivir efficacy. We also assess drug effi

SUBMITTER: Conway JM 

PROVIDER: S-EPMC8400702 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature